# Aurora Innovation, Inc.: financial statements, quarterly

AUR · Nasdaq · CIK 1828108 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/aur.md) · [Financials](/companies/aur/financials.md) · [Filings](/companies/aur/filings.md) · [Insiders](/companies/aur/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/aur/financials.md?period=annual).

## Income statement

| Line item | Unit | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | [0.0](/filings/0001828108-25-000139.md) | [0.0](/filings/0001828108-25-000157.md) | [0.0 d](/filings/0001828108-26-000016.md) | [0.0](/filings/0001828108-26-000052.md) | [1.0](/filings/0001828108-26-000077.md) | [1.0](/filings/0001828108-26-000094.md) | [1.0 d](/filings/0001828108-26-000016.md) | [1.0](/filings/0001828108-26-000052.md) | [2.0](/filings/0001828108-26-000077.md) | [3.0](/filings/0001828108-26-000094.md) |
| Cost of revenue | $m | not reported | not reported | [0.0](/filings/0001828108-25-000139.md) | [0.0](/filings/0001828108-25-000157.md) | [0.0 d](/filings/0001828108-26-000016.md) | [0.0](/filings/0001828108-26-000052.md) | [5.0](/filings/0001828108-26-000077.md) | [6.0](/filings/0001828108-26-000094.md) | [6.0 d](/filings/0001828108-26-000016.md) | [6.0](/filings/0001828108-26-000052.md) | [7.0](/filings/0001828108-26-000077.md) | [8.0](/filings/0001828108-26-000094.md) |
| Research and development | $m | [170 d](/filings/0001828108-26-000016.md) | [166](/filings/0001828108-25-000087.md) | [170](/filings/0001828108-25-000139.md) | [169](/filings/0001828108-25-000157.md) | [171 d](/filings/0001828108-26-000016.md) | [182](/filings/0001828108-26-000052.md) | [190](/filings/0001828108-26-000077.md) | [179](/filings/0001828108-26-000094.md) | [194 d](/filings/0001828108-26-000016.md) | [195](/filings/0001828108-26-000052.md) | [211](/filings/0001828108-26-000077.md) | [203](/filings/0001828108-26-000094.md) |
| Selling, general and administrative | $m | [28.0 d](/filings/0001828108-26-000016.md) | [27.0](/filings/0001828108-25-000087.md) | [28.0](/filings/0001828108-25-000139.md) | [27.0](/filings/0001828108-25-000157.md) | [28.0 d](/filings/0001828108-26-000016.md) | [29.0](/filings/0001828108-26-000052.md) | [36.0](/filings/0001828108-26-000077.md) | [38.0](/filings/0001828108-26-000094.md) | [39.0 d](/filings/0001828108-26-000016.md) | [44.0](/filings/0001828108-26-000052.md) | [50.0](/filings/0001828108-26-000077.md) | [49.0](/filings/0001828108-26-000094.md) |
| Operating income | $m | [(198) d](/filings/0001828108-26-000016.md) | [(193)](/filings/0001828108-25-000087.md) | [(198)](/filings/0001828108-25-000139.md) | [(196)](/filings/0001828108-25-000157.md) | [(199) d](/filings/0001828108-26-000016.md) | [(211)](/filings/0001828108-26-000052.md) | [(230)](/filings/0001828108-26-000077.md) | [(222)](/filings/0001828108-26-000094.md) | [(238) d](/filings/0001828108-26-000016.md) | [(244)](/filings/0001828108-26-000052.md) | [(266)](/filings/0001828108-26-000077.md) | [(257)](/filings/0001828108-26-000094.md) |
| Income tax | $m | [0.0 d](/filings/0001828108-26-000016.md) | [0.0](/filings/0001828108-25-000087.md) | [0.0](/filings/0001828108-25-000139.md) | [0.0](/filings/0001828108-25-000157.md) | [0.0 d](/filings/0001828108-26-000016.md) | [0.0](/filings/0001828108-26-000052.md) | [0.0](/filings/0001828108-26-000077.md) | [0.0](/filings/0001828108-26-000094.md) | [0.0 d](/filings/0001828108-26-000016.md) | [0.0](/filings/0001828108-26-000052.md) | [0.0](/filings/0001828108-26-000077.md) | [0.0](/filings/0001828108-26-000094.md) |
| Net income | $m | [(192) d](/filings/0001828108-26-000016.md) | [(165)](/filings/0001828108-25-000087.md) | [(182)](/filings/0001828108-25-000139.md) | [(208)](/filings/0001828108-25-000157.md) | [(193) d](/filings/0001828108-26-000016.md) | [(208)](/filings/0001828108-26-000052.md) | [(201)](/filings/0001828108-26-000077.md) | [(201)](/filings/0001828108-26-000094.md) | [(206) d](/filings/0001828108-26-000016.md) | [(223)](/filings/0001828108-26-000052.md) | [(270)](/filings/0001828108-26-000077.md) | [(234)](/filings/0001828108-26-000094.md) |
| Diluted EPS | $ per share | not reported | [(0.11)](/filings/0001828108-25-000087.md) | [(0.12)](/filings/0001828108-25-000139.md) | [(0.13)](/filings/0001828108-25-000157.md) | not reported | [(0.12)](/filings/0001828108-26-000052.md) | [(0.11)](/filings/0001828108-26-000077.md) | [(0.11)](/filings/0001828108-26-000094.md) | not reported | [(0.11)](/filings/0001828108-26-000052.md) | [(0.14)](/filings/0001828108-26-000077.md) | [(0.12)](/filings/0001828108-26-000094.md) |
| Basic EPS | $ per share | not reported | [(0.11)](/filings/0001828108-25-000087.md) | [(0.12)](/filings/0001828108-25-000139.md) | [(0.13)](/filings/0001828108-25-000157.md) | not reported | [(0.12)](/filings/0001828108-26-000052.md) | [(0.11)](/filings/0001828108-26-000077.md) | [(0.11)](/filings/0001828108-26-000094.md) | not reported | [(0.11)](/filings/0001828108-26-000052.md) | [(0.14)](/filings/0001828108-26-000077.md) | [(0.12)](/filings/0001828108-26-000094.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [501](/filings/0001828108-25-000028.md) | [454](/filings/0001828108-24-000088.md) | [402](/filings/0001828108-24-000127.md) | [263](/filings/0001828108-24-000140.md) | [211](/filings/0001828108-26-000016.md) | [170](/filings/0001828108-25-000087.md) | [206](/filings/0001828108-25-000139.md) | [87.0](/filings/0001828108-25-000157.md) | [221](/filings/0001828108-26-000094.md) | [273](/filings/0001828108-26-000052.md) | [136](/filings/0001828108-26-000077.md) | [141](/filings/0001828108-26-000094.md) |
| Current assets | $m | [1,217](/filings/0001828108-25-000028.md) | [1,142](/filings/0001828108-24-000088.md) | [1,043](/filings/0001828108-24-000127.md) | [1,275](/filings/0001828108-24-000140.md) | [1,254](/filings/0001828108-26-000016.md) | [1,193](/filings/0001828108-25-000087.md) | [1,340](/filings/0001828108-25-000139.md) | [1,284](/filings/0001828108-25-000157.md) | [1,317](/filings/0001828108-26-000094.md) | [1,272](/filings/0001828108-26-000052.md) | [1,252](/filings/0001828108-26-000077.md) | [1,065](/filings/0001828108-26-000094.md) |
| Total assets | $m | [2,235](/filings/0001828108-25-000028.md) | [2,089](/filings/0001828108-24-000088.md) | [1,914](/filings/0001828108-24-000127.md) | [2,265](/filings/0001828108-24-000140.md) | [2,138](/filings/0001828108-26-000016.md) | [2,071](/filings/0001828108-25-000087.md) | [2,214](/filings/0001828108-25-000139.md) | [2,510](/filings/0001828108-25-000157.md) | [2,343](/filings/0001828108-26-000094.md) | [2,185](/filings/0001828108-26-000052.md) | [2,167](/filings/0001828108-26-000077.md) | [2,007](/filings/0001828108-26-000094.md) |
| Current liabilities | $m | [111](/filings/0001828108-25-000028.md) | [110](/filings/0001828108-24-000088.md) | [81.0](/filings/0001828108-24-000127.md) | [93.0](/filings/0001828108-24-000140.md) | [105](/filings/0001828108-26-000016.md) | [125](/filings/0001828108-25-000087.md) | [79.0](/filings/0001828108-25-000139.md) | [84.0](/filings/0001828108-25-000157.md) | [111](/filings/0001828108-26-000094.md) | [134](/filings/0001828108-26-000052.md) | [110](/filings/0001828108-26-000077.md) | [110](/filings/0001828108-26-000094.md) |
| Total liabilities | $m | [250](/filings/0001828108-25-000028.md) | [231](/filings/0001828108-24-000088.md) | [197](/filings/0001828108-24-000127.md) | [247](/filings/0001828108-24-000140.md) | [263](/filings/0001828108-26-000016.md) | [286](/filings/0001828108-25-000087.md) | [223](/filings/0001828108-25-000139.md) | [219](/filings/0001828108-25-000157.md) | [203](/filings/0001828108-26-000094.md) | [221](/filings/0001828108-26-000052.md) | [214](/filings/0001828108-26-000077.md) | [211](/filings/0001828108-26-000094.md) |
| Shareholders' equity | $m | [1,985](/filings/0001828108-26-000016.md) | [1,858](/filings/0001828108-25-000139.md) | [1,717](/filings/0001828108-25-000157.md) | [2,018](/filings/0001828108-25-000157.md) | [1,875](/filings/0001828108-26-000094.md) | [1,785](/filings/0001828108-26-000077.md) | [1,991](/filings/0001828108-26-000094.md) | [2,291](/filings/0001828108-26-000094.md) | [2,140](/filings/0001828108-26-000094.md) | [1,964](/filings/0001828108-26-000077.md) | [1,953](/filings/0001828108-26-000094.md) | [1,796](/filings/0001828108-26-000094.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(133) d](/filings/0001828108-26-000016.md) | [(150)](/filings/0001828108-25-000087.md) | [(176) d](/filings/0001828108-25-000139.md) | [(143) d](/filings/0001828108-25-000157.md) | [(142) d](/filings/0001828108-26-000016.md) | [(142)](/filings/0001828108-26-000052.md) | [(144) d](/filings/0001828108-26-000077.md) | [(149) d](/filings/0001828108-26-000094.md) | [(146) d](/filings/0001828108-26-000016.md) | [(159)](/filings/0001828108-26-000052.md) | [(225) d](/filings/0001828108-26-000077.md) | [(170) d](/filings/0001828108-26-000094.md) |
| Capital expenditure | $m | [4.0 d](/filings/0001828108-26-000016.md) | [8.0](/filings/0001828108-25-000087.md) | [11.0 d](/filings/0001828108-25-000139.md) | [7.0 d](/filings/0001828108-25-000157.md) | [8.0 d](/filings/0001828108-26-000016.md) | [8.0](/filings/0001828108-26-000052.md) | [7.0 d](/filings/0001828108-26-000077.md) | [8.0 d](/filings/0001828108-26-000094.md) | [8.0 d](/filings/0001828108-26-000016.md) | [25.0](/filings/0001828108-26-000052.md) | [31.0 d](/filings/0001828108-26-000077.md) | [36.0 d](/filings/0001828108-26-000094.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [1,170](/filings/0001828108-24-000088.md) | [1,179](/filings/0001828108-24-000127.md) | [1,432](/filings/0001828108-24-000140.md) | [1,537](/filings/0001828108-25-000087.md) | [1,554](/filings/0001828108-25-000139.md) | [1,657](/filings/0001828108-25-000157.md) | [1,744](/filings/0001828108-26-000052.md) | [1,785](/filings/0001828108-26-000077.md) | [1,891](/filings/0001828108-26-000094.md) | [1,948](/filings/0001828108-26-000052.md) | [1,976](/filings/0001828108-26-000077.md) | [2,004](/filings/0001828108-26-000094.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 642,869,548 at 2021-11-03, from the cover of the [10-Q filed 2021-11-15](/filings/0001193125-21-329900.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 31, 2026, 15:25 ET. No prices; not investment advice.